Fermenta Biotech Ltd

Fermenta Biotec. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Fermenta Biotech Ltd

₹ 404 -0.76%
13 Dec - close price
dil.net BSE: 506414
About

Incorporated in 1951, Fermenta Biotech
Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]

Key Points

Business Overview:[1][2]
a) FBL is engaged in development
and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries. It is a global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
b) Company is involved in manufacturing
of APIs for muscle relaxant and anti-flatulent applications. It delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment & management.
c) Also, company has strategic investments in subsidiaries / associate companies primarily dealing in manufacturing and marketing bulk drugs and providing services of sporting and health awareness activities / education activities.
d) Company also deals in lease rental business for ITES properties developed in Than

Website BSE
  • Market Cap ₹ 1,188 Cr.
  • Current Price ₹ 404
  • High / Low ₹ 440 / 145
  • Stock P/E 145
  • Book Value ₹ 98.6
  • Dividend Yield 0.31 %
  • ROCE 3.20 %
  • ROE -5.59 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter
  • Company's working capital requirements have reduced from 137 days to 108 days

Cons

  • Stock is trading at 4.10 times its book value
  • The company has delivered a poor sales growth of -3.64% over past five years.
  • Company has a low return on equity of -2.65% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
100 93 96 92 98 55 105 82 57 99 97 78 95
84 91 78 87 95 65 86 72 71 74 92 77 76
Operating Profit 16 2 18 5 3 -10 19 11 -14 25 5 1 19
OPM % 16% 2% 18% 5% 3% -18% 18% 13% -24% 25% 6% 1% 20%
2 1 3 4 3 -19 -8 2 -6 3 5 3 3
Interest 4 4 4 4 5 5 6 5 4 5 3 3 4
Depreciation 6 7 6 7 9 6 6 6 6 6 6 6 6
Profit before tax 7 -7 10 -2 -8 -41 -1 2 -29 16 1 -6 12
Tax % 42% 13% 21% 8% 6% -8% 373% 0% 0% 38% 885% 0% 6%
4 -8 8 -3 -8 -38 -5 2 -29 10 -7 -6 11
EPS in Rs 1.53 -2.73 2.61 -0.88 -2.75 -12.70 -1.40 0.62 -9.70 3.35 -2.36 -1.98 3.87
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
117 139 142 155 164 302 403 292 376 397 349 335 369
94 113 126 134 152 209 248 225 293 335 330 307 319
Operating Profit 23 26 16 21 12 93 156 66 83 62 18 28 50
OPM % 20% 19% 11% 13% 7% 31% 39% 23% 22% 16% 5% 8% 14%
2 3 0 1 3 9 6 12 8 8 -20 4 14
Interest 5 5 4 6 10 14 21 20 19 18 21 17 16
Depreciation 9 10 9 8 10 12 12 15 20 26 28 25 25
Profit before tax 10 14 3 7 -6 76 129 43 52 27 -51 -10 23
Tax % 36% 24% 67% 61% 49% 28% 8% -37% 18% 44% 4% 143%
4 10 1 2 -9 46 117 60 43 15 -53 -24 8
EPS in Rs 1.51 2.86 0.17 -0.41 -4.14 12.21 42.71 20.23 15.46 5.25 -17.36 -7.84 2.88
Dividend Payout % 124% 29% 249% -51% -5% 2% 1% 24% 16% 23% -7% -16%
Compounded Sales Growth
10 Years: 9%
5 Years: -4%
3 Years: -4%
TTM: 23%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 122%
Stock Price CAGR
10 Years: 22%
5 Years: 15%
3 Years: 12%
1 Year: 165%
Return on Equity
10 Years: 10%
5 Years: 5%
3 Years: -3%
Last Year: -6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 2 2 2 2 2 2 5 14 14 14 14 14 14
Reserves 125 130 129 128 142 122 246 295 346 358 301 274 276
43 65 71 89 87 173 209 224 232 239 220 139 125
55 61 60 70 75 87 92 80 94 96 102 120 125
Total Liabilities 226 259 262 288 307 385 551 614 687 707 637 548 539
94 87 85 168 172 177 178 200 263 299 267 269 258
CWIP 15 36 65 6 5 4 22 71 57 35 45 2 6
Investments 11 17 18 15 18 10 8 0 0 0 3 0 0
105 118 94 99 112 193 344 342 367 373 321 277 274
Total Assets 226 259 262 288 307 385 551 614 687 707 637 548 539

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
23 14 15 4 2 59 90 34 63 43 116 105
-20 -25 -18 -13 7 -101 -97 -44 -41 -26 -55 -16
-8 13 1 10 -12 89 12 -47 -1 -22 -41 -91
Net Cash Flow -4 2 -2 1 -4 47 6 -57 21 -4 19 -1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 79 106 91 101 99 83 59 87 66 80 44 76
Inventory Days 225 149 125 160 208 234 347 594 441 380 309 245
Days Payable 134 120 95 113 147 183 169 260 169 154 109 182
Cash Conversion Cycle 171 136 122 148 160 134 237 421 338 306 244 139
Working Capital Days 72 73 4 20 115 90 97 202 171 180 123 108
ROCE % 8% 9% 3% 6% 2% 31% 41% 12% 13% 7% -0% 3%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
59.58% 59.58% 59.58% 59.58% 59.58% 59.58% 62.06% 62.06% 62.06% 62.06% 62.06% 62.06%
0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.05%
0.05% 0.05% 0.05% 0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
38.37% 38.37% 38.37% 38.38% 38.45% 38.46% 36.00% 36.04% 36.05% 36.05% 36.11% 36.41%
1.98% 1.98% 1.98% 1.98% 1.95% 1.95% 1.92% 1.89% 1.89% 1.89% 1.82% 1.47%
No. of Shareholders 18,57817,51817,47217,97117,61016,89716,14815,72115,15015,17814,58913,221

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls